Doxorubicin and cyclophosphamide treatment produces anxiety-like behavior and spatial cognition impairment in rats: Possible involvement of hippocampal neurogenesis via brain-derived neurotrophic factor and cyclin D1 regulation

Kitamura, Yoshihisa; Hattori, Sayo; Yoneda, Saori; Watanabe, S; Kanemoto, Erika; Sugimoto, Misaki; Kawai, Toshiki; Machida, Ayumi; Kanzaki, Hirotaka; Miyazaki, Ikuko; Asanuma, Masato; Sendo, Toshiaki

doi:10.1016/j.bbr.2015.06.007

Cited by 78 publications

(44 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is widely assumed that conventional chemotherapies do not cross the brain blood barrier (BBB). However, recent data reveal that agents such as doxorubicin, cyclophosphamide and cisplatin, do, in fact, cross the BBB, and thus may have effects on the decreased mitochondrial function, increase the oxidative stress and lead to morphological changes in the brain and consequently to neurophysiological dysfunction (Ahles & Saykin, ; Kitamura et al , ; Lomeli et al , ). Our findings revealed that HLS who received fewer chemotherapy cycles had better neurocognitive performance and were consistent with previously published data (Baudino et al , ), supporting these hypotheses.…”

Section: Discussionmentioning

confidence: 99%

Cognitive impairment in hodgkin lymphoma survivors

Trachtenberg¹,

Mashiach

Hayun

et al. 2018

Br J Haematol

View full text Add to dashboard Cite

Cancer-related cognitive impairment (CRCI) is commonly reported post-chemotherapy in adults with solid tumours. Hodgkin lymphoma (HL) mostly affects young adults. Data regarding CRCI in HL survivors (HLS) are scarce. The current study aimed to objectively assess CRCI incidence and characteristics in HLS. HLS, who completed first-line (chemotherapy ± radiation) therapy and remained in complete remission for 6 months to 5 years from therapy end, were evaluated. Age- and education-matched healthy individuals served as controls (n = 14). Test results were compared to population norms and healthy controls. Study participants completed self-reported questionnaires evaluating fatigue, depression, anxiety, quality of life and cognitive function. Subjects underwent neurocognitive evaluation, assessing processing speed, memory, attention, executive functions and intelligence domains. The present study included 51 HLS with a median age of 28 years, mean education of 14·5 ± 2·5 years. Complaints related to cognitive deterioration and fatigue were significantly more severe and frequent in HLS compared to healthy controls. Objective neurocognitive evaluation demonstrated that 30% of HLS were impaired in ≥2 cognitive domains. In conclusion, the present study demonstrates that fatigue and cognitive impairment, predominantly in executive functions and memory, constitute frequent and alarming findings in HLS. These adverse effects can persist and exert an impact on all aspects of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Cognitive impairment in hodgkin lymphoma survivors

Trachtenberg¹,

Mashiach

Hayun

et al. 2018

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…Mice that receive treatment with chemotherapeutic agents (eg, taxanes, antimetabolites, alkylating agents) mirror behaviors hypothesized to be homologous to the anxiety, depression, 15,16 and cognitive impairments observed in patients with cancer. 17,18 Most rodent studies report increases in these negative behaviors, although the duration and magnitude of behavioral changes vary.…”

Section: Chemotherapy Behavior and The Brain In Rodent Modelsmentioning

confidence: 99%

Gut microbiota‐immune‐brain interactions in chemotherapy‐associated behavioral comorbidities

Jordan

Loman

Bailey

et al. 2018

Cancer

View full text Add to dashboard Cite

Increasing scientific attention is focused on the gut-brain axis, including the ability of the gastrointestinal (GI) tract to modulate central nervous system function. Changes in the intestinal microbiome can influence affective-like behavior, cognitive performance, fatigue, and sleep in rodents and humans. Patients with cancer who are receiving chemotherapy experience similar negative behavioral changes and concurrent GI symptoms. These chemotherapy comorbidities can be long-lasting and may reduce patients' quality of life and motivation to comply with treatment. This review summarizes the clinical and preclinical evidence supporting a role for the intestinal microbiome in mediating behavioral comorbidities through peripheral immune activation in patients with cancer who are receiving chemotherapy. In addition, evidence suggesting that targeted modification of the intestinal microbiome during cancer treatment could ameliorate associated behavioral comorbidities is reviewed.

show abstract

“…Cognitive dysfunction during and following chemotherapy, often referred to as "chemobrain," has been largely reported in patients receiving chemotherapeutics whose cognitive problems worsened during treatment and were still evident 6 months after chemotherapy cessation (Kitamura, et al, 2015). This ranges from very subtle to more severe, with memory, processing speed, and more complex aspects of attention being most affected (Correa and Ahles, 2008).…”

Section: Introductionmentioning

confidence: 98%